OAOlusegun Adeyemo

Olusegun Adeyemo

*This is an algorithmically generated author record based on publicly available information.

Olusegun Adeyemo has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Yoruba Moral Philosophy and the Ethical Governance of Data Science Health Research in Africa

    by Clement Adebamowo, Simisola Akintola, Ayodele Jegede, Muhammad K. Imam‐Tamim, Ibrahim Uthman, Shawneequa Callier, Sally N. Adebamowo, Adeola Akintola, Peter Ikhane, Temidayo Ogundiran, et al.

    Data science health research (DSHR) which encompasses genomic biobanking, algorithmic clinical prediction, large‐scale secondary use of health data, and AI‐assisted diagnostics is expanding rapidly across Africa through initiatives such as the Human Heredity and Health in Africa (H3Africa) consortium and the Data Science for Health Discovery and Innovation in Africa (DS‐I Africa) program. Existing ethical governance frameworks based on Western principlism, Ubuntu‐based bioethics, and the CARE Principles for Indigenous Data Governance each capture part of the ethical terrain for governance of DSHR in Africa but gaps remain. In this paper, we apply a Yoruba moral philosophical framework, developed in a companion paper, to the five central challenges of DSHR governance in Yoruba communities: informed consent in big‐data contexts, algorithmic fairness, data sovereignty, secondary use of health data, and AI clinical decision support. Drawing on the six Yoruba moral principles that extend principlism including procedural communal deliberation ( Ifọgbọntáayésé ), moderate‐communitarian relational personhood, virtue‐based character ethics ( Ìwà/Omolúàbí ), intergenerational kinship obligations ( Àjọbí ), sacred‐epistemic confidentiality ( Awo ), and restorative‐adjudicative justice ( Ìlàjà ), we demonstrate that each generates concrete, operationalizable governance recommendations that exceed what principlism, Ubuntu‐bioethics, or CARE Principles supply individually. We present a comprehensive governance framework with specific institutional mechanisms: Community Data Stewardship Councils, tiered consent with lineage‐level governance, Omolúàbí‐ informed researcher assessment, ẹbọ ‐based benefit‐sharing, Awo ‐governed data classification, and ìlàjà restorative harm remediation. The framework positions Yoruba moral philosophy as one voice in a principled pluralism for the ethical governance of DSHR in Africa. It is designed to operate within, not alongside, the harmonized procedures and instruments, supplying locally grounded moral content at the points where those instruments require community engagement but leave its form unspecified. It is not a replacement for existing approaches but a substantive addition to the current governance landscape.

  • Open Access

    Dissolution of Continuity of Ethical Governance in Data Science Health Research: Diagnostic and Response Framework for Lifecycle Oversight

    by Clement Adebamowo, Sally N Adebamowo, Adeola Akintola, Peter Ikhane, Simisola Akintola, Temidayo Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad K Imam-Tamim, et al.

    Traditional research ethics governance was designed for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. In this viewpoint, we use DSHR broadly to include research using large health datasets and adjacent secondary uses of health data, models, and biological materials, including learning health systems, public health surveillance, quality improvement, operations, commercial product development, and artificial intelligence (AI)–enabled translational uses that rely on health data or material lineages. We introduce ethical governance continuity dissolution (EGCD), the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological material lineage, such that no coherent set of actors, instruments, or community processes can authorize, constrain, monitor, adjudicate, or remediate current use in relation to the persons and communities of origin. EGCD is distinct from consent staleness, function creep, contextual integrity violation, algorithmic drift, or a single defective data use agreement. It is the systemic condition in which several such failures together compromise the authority needed to govern current use. Building on our prior work on representational veracity and the continuity trap, we propose a diagnostic architecture that assesses six governance authority domains, applies three diagnostic criteria, scores each domain from 0 to 3 within a Continuity Authority Matrix (CAM), and stages severity from 0 to 4. We also propose an Ethical Continuity Governance and Response Mechanism (ECGRM) comprising a continuity registry, the CAM, trigger-based review, a Data Lifecycle Governance Officer function, a Continuity Dissolution Review Board, corrective and preventive action, cross-institutional audit, and community-governance integration. We use a publicly reported Royal Free–DeepMind Streams example to show how domain scores can identify stage 2 or 3 risk without converting the framework into a retrospective legal judgment. Implementation is proportionate, so these functions may operate within existing structures, particularly in underresourced institutions. The score and staging thresholds are conceptual triage aids, not validated metrics or automated determinations of ethical permissibility, and they require empirical validation and interrater reliability testing. Their purpose is to prevent the silent loss of governance authority while data, models, and biological materials continue to affect the lives, identities, and community standing of the persons and groups from whom they were derived. Lawful public health surveillance under a competent authority is a legitimate governance handoff, not EGCD; EGCD arises when authority is not transferred, traceable, accountable, or remediable. This viewpoint is addressed to research ethics committees and institutional review boards, data access committees, data stewards, biobank and registry leaders, AI governance teams, regulators, funders, community governance bodies, and investigators.


  • Open Access

    Representational Veracity in Data Science Health Research: Targets, Proxies, Labels, and Descriptors

    by Clement Adebamowo, Sally N Adebamowo, Adeola Akintola, Peter Ikhane, Simisola Akintola, Temidayo Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad K Imam-Tamim, et al.

    Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because each presupposes an answer to a prior question that is seldom asked directly. That is, “do the targets, proxies, labels, classifications, ontologies, and population descriptors on which a current study rests still truthfully represent the persons, populations, and phenomena they are taken to describe, at the point of use rather than the point of collection?” In this viewpoint, we name that question representational veracity (RV) and develop it as a construct for upstream ethical review. Our aims are to define RV and derive the domains along which it can be assessed; to demonstrate that it asks something that measurement validity, critical data studies, and algorithmic fairness do not; and to translate it into instruments that review bodies can use. We derive 4 assessment domains of RV analytically, asking for each transition in the data journey what must remain stable for a stored artifact still to stand for what it originally stood for. The resulting domains are material provenance, informational descriptors, normative authorization, and relational community. These domains interact but do not substitute for one another. Intact provenance cannot repair a poorly chosen target, and a transparent labeling process cannot confer authorization it never had. Drawing on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health AI governance, we show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, too unstable, or too normatively misdirected for the proposed use. We examine 4 recurrent failure modes, proxy substitution, category misassignment, label generation error, and descriptor sedimentation, anchoring each in a published case, and we present a counterpoint in which better representation reveals rather than conceals inequity. A polygenic risk score (PRS) case study illustrates all 4 domains and shows how a score can misclassify risk in the populations least represented in its derivation while its code, pipeline, and internal validation statistics remain intact. We then translate the framework into practice using 10 reviewer prompts that an editor can paste into a review form, a justification template and scoring rubric provided as appendices, a tiered model that triggers full review only for subgroup, equity, transportability, public health, or clinical implementation claims, and a graded account of what should follow an adverse finding. Our argument is that existing governance mechanisms require an upstream layer. Investigators should be asked to justify not only whether their models perform, but whether their representations are truthful enough for the claims at hand. The intended audience is investigators, informaticians, research ethics committees, institutional review boards, data access committees, funders, regulators, and journal editors.


  • Open Access

    The Continuity Trap in Data Science Health Research

    by Clement Adebamowo, Sally Nneoma Adebamowo, Adeola Akintola, Peter Ikhane, Simisola Akintola, Temidayo Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad Imam-Tamim, et al.

    Secondary use is now the ordinary condition of data science health research rather than an exception to it. Electronic health records collected for clinical care become prediction tools and inputs for generative AI; imaging archives become foundation-model corpora; genomic datasets become resources for polygenic risk scores; and legacy biospecimens become renewable, indefinitely distributable cell lines. Governance has responded by emphasizing verifiable instruments such as provenance logs, repository approvals, broad-consent forms, data-use agreements, model cards, records of processing, and locality-preserving architectures. These instruments are necessary, and they answer real questions about lineage, privacy, institutional responsibility, and accountability, but they are not sufficient to establish that a present use remains ethically justified. We define ethical continuity as the persistence of normatively relevant relationships between the original conditions of data generation or material collection and subsequent downstream uses, such that current uses remain justifiable in light of the expectations, permissions, meanings, and relational obligations present at entrustment. We then define the Continuity Trap as a review-stage governance error in which a salient signal of continuity in one domain is treated as sufficient evidence of ethical continuity overall, causing inquiry into the remaining domains to close prematurely. The trap is not ordinary noncompliance, ethics creep, or a demand for universal rereview; it is a cross-domain inference error that can arise even in careful, good-faith review. We distinguish it from proxy closure, of which it is a continuity-specific subtype, and from Goodhart’s and Campbell’s laws, which describe how measures degrade once they become targets. We operationalize ethical continuity across 4 domains: provenance, semantics, authorization, and relational standing, developed in our Representational Veracity framework, and we show that these domains can diverge as data are linked, transformed, modeled, and redeployed. We identify the institutional mechanisms—provenance privilege, descriptor sedimentation, authorization fossilization, and community effacement—that cause auditable signals to be overread, and we examine how the US Health Insurance Portability and Accountability Act (HIPAA) of 1996, the General Data Protection Regulation, the European Health Data Space, US Food and Drug Administration guidance, the US National Institute of Standards and Technology (NIST) AI Risk Management Framework, and federated-learning governance can reduce risk while still inducing continuity traps. We apply the framework to consent and nonconsent settings, including public health, immunization, syndromic, and wastewater surveillance, polygenic risk scores, induced pluripotent stem cells, federated learning, and health-related large language models. The policy implication is trigger-based continuity review: rather than rereviewing every reuse, investigators and reviewers should identify the weakest continuity domain at the present data stage and impose a domain-matched safeguard, recorded in a short continuity statement. This reframing is intended for the committees, repositories, funders, and governance bodies that decide whether reuse may proceed, and it matters most in cross-border and low-resource settings. Provenance should begin ethical review; it should not end it.


  • Open Access

    Representational Veracity in Data Science Health Research: A Companion Viewpoint on Targets, Proxies, Labels, and Descriptors (Preprint)

    by Clement Adebamowo, Sally N Adebamowo, Adeola Akintola, Peter Ikhane, Simisola Akintola, Temidayo Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad K Imam-Thamim, et al.

    UNSTRUCTURED Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because they presuppose that the targets, proxies, labels, classifications, ontologies, and population descriptors already truthfully represent the populations and phenomena they claim to describe. That prior question is often left unexamined. In this Viewpoint, we introduce representational veracity (RV) as a companion concept to the Continuity Trap (CT) framework, grounded in a persistence-based account of representational adequacy developed in the parent framework manuscript. The Continuity Trap names the governance error in which a salient signal of continuity in one domain - technical, administrative, or infrastructural - is treated as sufficient evidence that ethical continuity has been preserved across all domains. In contrast, RV asks whether stored data continue to accurately and responsibly represent the persons, communities, and phenomena from which they were derived — at the point of use, not merely the point of collection. We draw on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health artificial-intelligence (AI) governance to show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, unstable, or normatively misdirected for the proposed use. Our analysis proceeds through the four-domain representational-veracity architecture (material provenance, informational descriptors, normative authorization, relational community), examines four recurrent failure modes (proxy substitution, category misassignment, label-generation error, descriptor sedimentation), and applies these to a polygenic risk score (PRS) use case. Our argument is not that existing governance mechanisms are wrong but that they need an additional upstream layer. Investigators should be required to justify not only whether their models perform, but also whether their representations are truthful enough for the clinical, public health, or policy claims at hand.

  • Open Access

    Dissolution of Continuity of Ethical Governance in Data Science Health Research: A Diagnostic and Response Framework for Lifecycle Oversight (Preprint)

    by Clement Adebamowo, Sally N. Adebamowo, Adeola Akintola, Peter A. Ikhane, Simisola Akintola, Temidayo O. Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad Imam-Thamim, et al.

    UNSTRUCTURED Background: Traditional research ethics governance was built for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. The ethical problem is not simply that individual instruments such as consent forms, IRB approvals, data access agreements, model cards, or privacy notices become outdated. It is that, across the lifecycle, the authorities that make these instruments ethically meaningful may lose jurisdiction, standing, evidentiary force, or remedial control. Conceptual contribution: This paper introduces Ethical Governance Continuity Dissolution (EGCD): the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological-material lineage, such that no coherent assemblage of actors, instruments, rules, or community processes can any longer authorize, constrain, monitor, adjudicate, or remediate current use. EGCD differs from consent staleness, function creep, contextual integrity violations, algorithmic drift, and the continuity trap because it names the systemic condition in which several such failures become mutually reinforcing. Framework: Building on prior work on representational veracity and the continuity trap, we develop a six-domain authority taxonomy, diagnostic criteria, staging categories, and a prototype Ethical Continuity Dissolution Score. We then propose an Ethical Continuity Governance and Response Mechanism consisting of a continuity registry, continuity authority matrix, trigger-based lifecycle review, a Data Lifecycle Governance Officer, a Continuity Dissolution Review Board, cross-institutional audits, and community governance integration. Implications: EGCD provides a practical vocabulary and governance architecture for diagnosing and managing the loss of ethical governance continuity in global DSHR. The goal is not to freeze all original consent conditions indefinitely, but to prevent silent loss of governance authority as data, models, and biological materials move through increasingly complex research and translational ecosystems.

  • Open Access

    The Continuity Trap in Data Science Health Research (Preprint)

    by Clement Adebamowo, Sally Nneoma Adebamowo, Adeola Akintola, Peter Ikhane, Simisola Akintola, Temidayo Ogundiran, Ayodele Jegede, Olusegun Adeyemo, Shawneequa Callier, Muhammad Imam-Thamim, et al.

    UNSTRUCTURED Secondary use is now the ordinary course for data and biospecimens in health research. Clinical records collected for care become training data for prediction tools; archived images become foundation models; legacy biospecimens become renewable cell lines; and large corpora are repurposed to build health-related language models. Governance nevertheless continues to privilege the most obvious signals of persistence such as provenance logs, repository approvals, broad-consent forms, locality-preserving architectures, and documented ingestion pipelines, as if they were sufficient to establish legitimacy. They are not. In this article, we define the Continuity Trap as a continuity-specific form of proxy closure: a review-stage governance error in which a salient continuity signal in one domain is treated as sufficient reason to stop inquiry into whether semantic, authorization, and relational continuity have also been preserved. The concept is narrower than generic proceduralism, ethics washing, or proxy failure, because it isolates a specific inferential mistake in secondary-use review; and it is distinct from Goodhart’s and Campbell’s laws, which describe the dynamic corruption of measures once they become targets. The Continuity Trap can occur at an earlier stage, even in good-faith review. Continuity of ethical governance in data science health research must therefore be assessed across four domains, provenance, semantics, authorization, and relational standing, that we previously developed in our Representational Veracity framework. These domains can diverge as data are linked, transformed, modeled, and redeployed. We use vignettes from polygenic risk scores, legacy induced pluripotent stem cell derivation, federated learning, and health-related large language models to illustrate the problem. The policy implication is not universal re-review, but triggered continuity review whenever visible continuity is likely to be overread.


  • Open Access

    Knowledge and Recommendations of Stakeholders Regarding Ethical Oversight of Data Science Health Research: Protocol for a Qualitative Study

    by Clement Adebamowo, Adeola Akintola, Oluchi C Maduka, Peter Ikhane, Ayodele Jegede, Shawneequa Callier, Simisola Akintola, Temidayo Ogundiran, Olusegun Adeyemo, Sally N Adebamowo

    Background: Data science health research (DSHR) uses novel computational methods and high-performance computing to analyze big data from conventional and nonconventional health and related sources to generate novel insights and communications. DSHR creates assets but generates ethical, legal, and social challenges. Key gaps in current ethical oversight of DSHR include blurred boundaries between research and nonresearch data use, inadequate protection of data donors, power imbalances that risk extractive research practices, algorithmic biases, and regulatory inadequacies. Nigeria, a typical low- and middle-income country with rapidly expanding DSHR, exemplifies this environment and concerns. Objective: This study will elicit answers from Nigerian DSHR stakeholders and contribute to understanding the ethical, legal, and social implications (ELSI) of DSHR and developing novel ethical oversight frameworks. Methods: Between October 2024 and January 2025, we conducted Key Informant Interviews with 65 stakeholders of 87 individuals. The Key Informant Interview guide comprised 11 construct-based question domains addressing awareness of policies and laws, ethical oversight processes, ELSI considerations in policy development, experiences addressing DSHR challenges, organizational and procedural frameworks, ideal oversight components, stakeholder roles, research impact on ethics and policy, regulatory influences on research practices, equity-enhancing policies, and balanced regulations. The interviews lasted 60-90 minutes and were transcribed. We analyzed the transcripts using a hybrid deductive-inductive approach. A priori codes derived from research objectives provided the analytical framework while allowing for the identification of emergent concepts. The iterative 3-level coding process involved initial code generation, evaluation, and refinement, with codes grouped into thematic families and semantic networks representing hierarchical concept relationships. Query tools and Boolean operators were used to interrogate the codes to extract findings. Results: Of 87 invited individuals, 22 (25%) were unable to participate. The 65 participants (age: mean 47.9, SD 7.9 years; 50/65, 77% male) included data science health researchers (25/65, 39%), biomedical researchers (17/65, 26%), Health Research Ethics Committee members (12/65, 19%), and policymakers (11/65, 17%). Most held doctoral degrees (38/65, 57%) and were affiliated with academic institutions (45/65, 69%) and government organizations (26/65, 40%), and had received general research ethics training (50/65, 77%). However, only 12% (8/65) had received predominantly short-duration ethics-specific DSHR training, while 92% (60/65) acknowledged the need for specialized DSHR ethics education. As of January 2025, the interview transcripts have been generated, with checking completed, with qualitative analysis scheduled for completion by March 2025 and completion of primary manuscripts by the end of 2025. Conclusions: This study will generate stakeholder-informed recommendations for ethical oversight of DSHR that address issues relating to broad consent, ELSI, data ownership, benefit-sharing, and donor protection in resource-limited settings. Our findings will inform global DSHR and research ethics communities on the development of contextually appropriate oversight mechanisms that promote equitable partnerships, co-ownership, and tiered data governance. International Registered Report Identifier (IRRID): DERR1-10.2196/78557


  • Strengthening Research Ethics Capacity in West Africa, 2015–2024

    by Kyle Ferguson, Clement Adebamowo, Adebayo O. Adejumo, Temidayo Ogundiran, Muktar H. Aliyu, Elisa J. Gordon, Zubairu Iliyasu, Christopher Agulanna, Shehu U. Adamu, Olusegun Adeyemo, et al.

    This article reviews the development and evolution of Fogarty International Center–funded research ethics training programs in West Africa over the past decade. In response to local and global challenges in bioethics and biomedical research, these programs are fostering ethical awareness, shaping local and national ethics review systems, and enhancing bioethics capacity in the region. These efforts have expanded alongside increased democratic governance, technological advances, and significant increases in global research funding and international research collaborations, particularly related to HIV/AIDS and malaria. We believe that the West Africa Bioethics (WAB) Training Program in Nigeria played a central role in this growth, serving as a model for subsequent programs in Ghana, Mali, and The Gambia. This paper describes the nature, successes, and challenges of these programs. It also outlines an agenda and strategies for future work to enhance research ethics and bioethics capacities in the region, both in terms of education and governance.


  • Open Access

    Knowledge and Recommendations of Stakeholders Regarding Ethical Oversight of Data Science Health Research: Protocol for a Qualitative Study (Preprint)

    by Clement Adebamowo, Adeola Akintola, Oluchi C Maduka, Peter Ikhane, Ayodele Jegede, Shawneequa Callier, Simisola Akintola, Temidayo Ogundiran, Olusegun Adeyemo, Sally N Adebamowo

    BACKGROUND Data science health research (DSHR) uses novel computational methods and high-performance computing to analyze big data from conventional and nonconventional health and related sources to generate novel insights and communications. DSHR creates assets but generates ethical, legal, and social challenges. Key gaps in current ethical oversight of DSHR include blurred boundaries between research and nonresearch data use, inadequate protection of data donors, power imbalances that risk extractive research practices, algorithmic biases, and regulatory inadequacies. Nigeria, a typical low- and middle-income country with rapidly expanding DSHR, exemplifies this environment and concerns. OBJECTIVE This study will elicit answers from Nigerian DSHR stakeholders and contribute to understanding the ethical, legal, and social implications (ELSI) of DSHR and developing novel ethical oversight frameworks. METHODS Between October 2024 and January 2025, we conducted Key Informant Interviews with 65 stakeholders of 87 individuals. The Key Informant Interview guide comprised 11 construct-based question domains addressing awareness of policies and laws, ethical oversight processes, ELSI considerations in policy development, experiences addressing DSHR challenges, organizational and procedural frameworks, ideal oversight components, stakeholder roles, research impact on ethics and policy, regulatory influences on research practices, equity-enhancing policies, and balanced regulations. The interviews lasted 60-90 minutes and were transcribed. We analyzed the transcripts using a hybrid deductive-inductive approach. A priori codes derived from research objectives provided the analytical framework while allowing for the identification of emergent concepts. The iterative 3-level coding process involved initial code generation, evaluation, and refinement, with codes grouped into thematic families and semantic networks representing hierarchical concept relationships. Query tools and Boolean operators were used to interrogate the codes to extract findings. RESULTS Of 87 invited individuals, 22 (25%) were unable to participate. The 65 participants (age: mean 47.9, SD 7.9 years; 50/65, 77% male) included data science health researchers (25/65, 39%), biomedical researchers (17/65, 26%), Health Research Ethics Committee members (12/65, 19%), and policymakers (11/65, 17%). Most held doctoral degrees (38/65, 57%) and were affiliated with academic institutions (45/65, 69%) and government organizations (26/65, 40%), and had received general research ethics training (50/65, 77%). However, only 12% (8/65) had received predominantly short-duration ethics-specific DSHR training, while 92% (60/65) acknowledged the need for specialized DSHR ethics education. As of January 2025, the interview transcripts have been generated, with checking completed, with qualitative analysis scheduled for completion by March 2025 and completion of primary manuscripts by the end of 2025. CONCLUSIONS This study will generate stakeholder-informed recommendations for ethical oversight of DSHR that address issues relating to broad consent, ELSI, data ownership, benefit-sharing, and donor protection in resource-limited settings. Our findings will inform global DSHR and research ethics communities on the development of contextually appropriate oversight mechanisms that promote equitable partnerships, co-ownership, and tiered data governance. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/78557